Eli Lilly and Co (LLY) Stock Analysis
Verdict: BUY
Mounjaro and Zepbound growth (+63% cardiometabolic revenue) justifies the 42x P/E premium, but high capital intensity remains a FCF drag.
Investment score: 72/100
Analysis as of
Is Eli Lilly and Co stock worth reviewing? AI model thesis
The AI model views LLY as a core growth holding despite a fair-value gap, citing unrivaled metabolic leadership and margin expansion.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 95/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 90/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 75/100 (weight 15%)
Eli Lilly and Co opportunities and risks
What speaks for LLY
- GLP-1 Market Dominance
What speaks against LLY
- Competitive Disruption in GLP-1s
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| LLY | 41.8x | 15.4x | 34.3x | 83.5% | 35.0% | 1.2% |
| JNJ | 29.2x | 6.3x | 20.1x | 69.1% | 21.8% | 2.9% |
| MRK | 35.8x | 4.8x | 19.1x | 75.9% | 13.6% | 4.5% |
| PFE | 19.1x | 2.3x | 12.3x | 69.3% | 11.8% | 6.6% |
| BMY | 17.1x | 2.6x | 11.6x | 68.7% | 15.0% | 9.6% |
| RPRX | 23.6x | 10.3x | 19.7x | 100.0% | 33.9% | 10.6% |
| Peer median | 23.6x | 4.8x | 19.1x | 69.3% | 15.0% | 6.6% |
Frequently asked questions about Eli Lilly and Co (LLY)
Is LLY stock a good investment?
The cached TradeMates AI model rates Eli Lilly and Co as BUY with an investment score of 72/100. The AI model views LLY as a core growth holding despite a fair-value gap, citing unrivaled metabolic leadership and margin expansion. This is algorithmic model output, not personal investment advice.
Is LLY stock a buy?
The TradeMates model verdict for LLY is BUY with an investment score of 72/100. Treat this as a model signal to review, not a personal buy recommendation.